Mandate

Vinge has advised Stendörren in connection with a bond issue of up to SEK 1,000 million

August 14, 2017

Vinge has advised Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with a bond issue of up to SEK 1,000 million senior unsecured floating rate bonds.

The bonds have a tenor of three years and a floating interest rate of three-months Stibor plus 4 per cent. ABG Sundal Collier AB and Swedbank have acted as financial advisors to Stendörren. Swedbank also acted as Issuing Agent.

The proceeds from the initial bond issue will primarily be used for refinancing of Stendörren’s outstanding SEK 750 million bonds, which will be made through a repurchase offer. The proceeds from the bond issue will also be used for acquisitions, investments and general corporate purposes. 

In accordance with the terms and conditions, the bonds are intended to be listed and admitted to trading on the corporate bond list at Nasdaq Stockholm shortly. As a result, the Company has prepared a prospectus which today has been approved by and registered with the Swedish Financial Supervisory Authority.

Vinges team consisted of Louise Brorsson Salomon, David Andersson, Sabina Börjesson, Josefine Larsson, André Isacson, Lionardo Ojeda and William Kåge

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024